NCCN Congress: Hematologic Malignancies | Conferences

Standard of Care in Newly Diagnosed Myeloma

October 19, 2021

Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.

Treating Post-MPN Acute Leukemia Remains an Unmet Medical Need

October 18, 2021

In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.

Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients

October 11, 2020

During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.

Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis

October 11, 2020

During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.